Myriad Genetics (MYGN) Stock Price Target 2026

The average analyst price target for Myriad Genetics is $9.86, 59.0% above the current price. Of 13 analysts, 4 rate it Buy, 5 Hold and 4 Sell. Targets range from $2 to $21. The latest change came on Nov 5, 2026, when TD Cowen raised its price target on Myriad Genetics from $4.50 to $6.75 and kept a Hold rating.

The Average Analyst Price Target for Myriad Genetics is $9.86.

Price Target Range — 12 Quarters

Analyst Consensus — 13 Analysts

4Buy

5Hold

4Sell

Consensus RatingEqual-Weight# Analysts13Avg. Consensus PT$9.86Upside to Avg. PT+59.0%

Rating Trend — Last 9 Months

Latest Upgrades and Downgrades for Myriad Genetics Stock

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 5, 2026	TD Cowen	Kyle Boucher	PT Raise	Hold	$5→$7
Nov 5, 2026	Leerink Partners	Puneet Souda	PT Raise	Market Perform	$5→$8
Oct 13, 2026	TD Cowen	Kyle Boucher	PT Raise	Hold	$4→$5
Oct 2, 2026	Craig-Hallum	John Wilkin	PT Raise	Buy	$4→$8
Sep 9, 2026	UBS	Lu Li	PT Cut	Neutral	$6→$4
Sep 1, 2026	Piper Sandler	David Westenberg	Downgrade	Overweight→Underweight	$5→$2
Aug 18, 2026	Stephens & Co.	Mason Carrico	PT Cut	Equal-Weight	$5→$3
Aug 3, 2026	Wells Fargo	Evan Stampler	PT Cut	Equal-Weight	$6→$3
Jul 31, 2026	TD Cowen	Kyle Boucher	PT Cut	Hold	$6→$4
May 6, 2026	TD Cowen	Kyle Boucher	PT Cut	Hold	$7→$6
May 6, 2026	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$6→$6
Feb 24, 2026	UBS	Lu Li	PT Cut	Neutral	$8→$6
Feb 24, 2026	Wells Fargo	Brandon Couillard	PT Cut	Equal-Weight	$7→$6
Nov 11, 2025	Piper Sandler	Dave Weiner	PT Cut	Overweight	$9→$9
Nov 5, 2025	Wells Fargo	Brandon Couillard	PT Raise	Equal-Weight	$6→$7
Nov 4, 2025	TD Cowen	Dan Brennan	PT Raise	Hold	$8→$9
Nov 4, 2025	UBS	Lu Li	PT Raise	Neutral	$6→$8
May 21, 2025	Scotiabank	Sung Ji Nam	Downgrade	Sector Outperform→Sector Perform	$20→$6
May 15, 2025	Piper Sandler	Dave Weiner	PT Cut	Overweight	$13→$9
May 8, 2025	Wells Fargo	Brandon Couillard	Downgrade	Overweight→Equal-Weight	$22→$6